EXTON, Pa.--(BUSINESS WIRE)--Morphotek®, Inc., a subsidiary of Eisai Corporation of North America, announced today that it has signed a Sponsored Research Agreement with The University of Pennsylvania to fund research for the development of therapeutic antibody candidates targeting an antigen associated with hypoxic regions in tumors. Hypoxia is a condition in which suboptimal oxygen concentrations exist in tissues.
